# ICOTYDE (icotrokinra) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/icotrokinra

> The FDA approved ICOTYDE (icotrokinra), sponsored by JOHNSON & JOHNSON (JNJ), on August 5, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | ICOTYDE (icotrokinra) |
| Codes | JNJ-2113, JNJ-77242113 |
| Sponsor | JOHNSON & JOHNSON (JNJ) https://sec-api.dev/companies/jnj/catalysts |
| Indications | [moderately-to-severely active ulcerative colitis](https://sec-api.dev/indications/moderately-to-severely-active-ulcerative-colitis), moderately-to-severely active uc, [moderately to severely active ulcerative colitis](https://sec-api.dev/indications/moderately-to-severely-active-ulcerative-colitis), moderately to severely active ulcerative colitis3, [Arthritis, Psoriatic](https://sec-api.dev/indications/arthritis-psoriatic), [Colitis, Ulcerative](https://sec-api.dev/indications/colitis-ulcerative), [Crohn Disease](https://sec-api.dev/indications/crohn-disease) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### Jul 2023: topline data readout

- Status: completed, positive. Date confidence: month.
- First seen 2025-02-21, last confirmed 2025-02-21.
- SEC Form 10-K (accession 0001558370-25-001317): "In July 2023, we announced updated positive topline results from the trial, which were presented by JNJ at the World Congress of Dermatology in Singapore." https://www.sec.gov/Archives/edgar/data/1377121/000155837025001317/ptgx-20241231x10k.htm

### November 18, 2024: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3.
- First seen 2024-11-18, last confirmed 2025-02-21.
- SEC Form 10-K (accession 0001558370-25-001317): "In November 2024, we announced positive topline results from ICONIC-LEAD and ICONIC-TOTAL Phase 3 trials of icotrokinra in individuals 12 years of age and older with moderate to severe plaque psoriasis." https://www.sec.gov/Archives/edgar/data/1377121/000155837025001317/ptgx-20241231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-24-120165): "Calif. - November 18, 2024 - Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced positive topline results from its collaboration with Johnson & Johnson, in ICONIC-LEAD1 and ICONIC-TOTAL2, two pivotal Phase 3 investigational studies of icotrokinra (JNJ-2113, formerly PN-235), the first-in-class targeted oral peptide that selectively blocks the IL-23 receptor, in individuals 12 years of age and older with moderate to severe plaque psoriasis (PsO)." https://www.sec.gov/Archives/edgar/data/1377121/000110465924120165/tm2428765d1_ex99-1.htm

### 2025: NDA/BLA submission

- Status: scheduled. Date confidence: year. Stage: 3.
- First seen 2025-03-10, last confirmed 2025-03-10.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-021986): "Two novel peptides, icotrokinra and rusfertide, derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA expected in 2025." https://www.sec.gov/Archives/edgar/data/1377121/000110465925021986/tm258665d1_ex99-1.htm

### March 10, 2025: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 2. Indication: moderately to severely active ulcerative colitis3.
- First seen 2025-02-21, last confirmed 2025-11-06.
- SEC Form 10-Q (accession 0001104659-25-107816): "In March 2025, we announced positive topline results from the ANTHEM-UC (NCT06049017) trial, a 252-patient randomized, controlled Phase 2b trial of icotrokinra in adults with moderately-to-severely active ulcerative colitis." https://www.sec.gov/Archives/edgar/data/1377121/000110465925107816/ptgx-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-010534): "In March 2025, we announced positive topline results from the ANTHEM-UC (NCT06049017) trial, a 252-patient randomized, controlled Phase 2b trial of icotrokinra in adults with moderately-to-severely active ulcerative colitis." https://www.sec.gov/Archives/edgar/data/1377121/000155837025010534/ptgx-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-006530): "In March 2025, we announced positive topline results from the Phase 2b Anthem-UC trial of icotrokinra in adults with moderately-to-severely active UC." https://www.sec.gov/Archives/edgar/data/1377121/000155837025006530/ptgx-20250331x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-021986): "Calif., March 10, 2025 - Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced positive topline results from ANTHEM-UC, a Phase 2b study of icotrokinra (JNJ-2113), the first investigational targeted oral peptide that selectively blocks the IL-23 receptor, in adults with moderately to severely active ulcerative colitis (UC)." https://www.sec.gov/Archives/edgar/data/1377121/000110465925021986/tm258665d1_ex99-2.htm
- SEC Form 10-K (accession 0001558370-25-001317): "Topline results for the ANTHEM trial for icotrokinra in UC are expected in the first quarter of 2025." https://www.sec.gov/Archives/edgar/data/1377121/000155837025001317/ptgx-20241231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-015897): "Topline results for icotrokinra Phase 2b ANTHEM clinical trial in moderate to severe ulcerative colitis expected in March 2025" https://www.sec.gov/Archives/edgar/data/1377121/000110465925015897/tm257151d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-015897): "Topline results for the Phase 2b ANTHEM multicenter, randomized, placebo- controlled, dose-ranging study of icotrokinra for the treatment of moderately to severely active ulcerative colitis3, are expected in March 2025." https://www.sec.gov/Archives/edgar/data/1377121/000110465925015897/tm257151d1_ex99-1.htm

### Q2 2025: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2025-02-21, last confirmed 2025-02-21.
- SEC Form 10-K (accession 0001558370-25-001317): "Topline results for the ICONIC-ADVANCE 1, ICONIC-ADVANCE 2, and pustular/erythrodermic psoriasis trials are expected in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1377121/000155837025001317/ptgx-20241231x10k.htm

### March 17, 2026: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Icotyde | icotrokinra | 3/17/2026 | To treat moderate-to-severe plaque psoriasis in patients 12 years and older who weigh at least 40 kg and who are candidates for systemic therapy or phototherapy Drug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
- openFDA Drugs@FDA: "NDA220149 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20260317, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product ICOTYDE (ICOTROKINRA HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA220149%22

### May 25, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Arthritis, Psoriatic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06878404 (A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-25 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT06878404

### August 5, 2026: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-08-05, last confirmed 2026-08-05.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-091099): "March 18, Protagonist announced that Johnson & Johnson received U.S. FDA approval of ICOTYDE for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy." https://www.sec.gov/Archives/edgar/data/1377121/000110465926091099/tm2622272d1_ex99-1.htm

### Feb to May 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Arthritis, Psoriatic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06807424 (A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-10 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT06807424

### February 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Arthritis, Psoriatic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06807424 (A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-10 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT06807424

### Jan to Apr 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Colitis, Ulcerative.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07196748 (A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-14 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT07196748

### January 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Colitis, Ulcerative.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07196748 (A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-14 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT07196748

### Sep to Dec 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Crohn Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07196722 (A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-09-19 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT07196722

### September 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Crohn Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07196722 (A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-09-19 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." https://clinicaltrials.gov/study/NCT07196722

## Same indication

- [Etrasimod](https://sec-api.dev/pdufa/etrasimod) (PFE)
- [Tremfya (guselkumab)](https://sec-api.dev/pdufa/guselkumab) (JNJ)
- [Guselkumab subcutaneous](https://sec-api.dev/pdufa/guselkumab-subcutaneous) (JNJ)
- [JNJ-88545223](https://sec-api.dev/pdufa/jnj-88545223) (JNJ)
- [LY4395089](https://sec-api.dev/pdufa/ly4395089) (LLY)
- [Zeposia (ozanimod hydrochloride)](https://sec-api.dev/pdufa/ozanimod) (BMY)
- [Sonelokimab](https://sec-api.dev/pdufa/sonelokimab) (MLTX)
- [SPY002](https://sec-api.dev/pdufa/spy002) (SYRE)
- [SPY003](https://sec-api.dev/pdufa/spy003) (SYRE)
- [Tev-48574 dose regimen a](https://sec-api.dev/pdufa/tev-48574-dose-regimen-a) (TEVA)
- [WEZLANA® (ustekinumab)](https://sec-api.dev/pdufa/ustekinumab) (JNJ)
- [Ustekinumab dose based on bsa and body weight](https://sec-api.dev/pdufa/ustekinumab-dose-based-on-bsa-and-body-weight) (JNJ)
- [Entyvio® (vedolizumab)](https://sec-api.dev/pdufa/vedolizumab) (TAK)

Calendar months: [February 2027](https://sec-api.dev/fda-calendar/2027-02), [January 2028](https://sec-api.dev/fda-calendar/2028-01), [September 2028](https://sec-api.dev/fda-calendar/2028-09)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/icotrokinra.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ICOTYDE (icotrokinra) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/icotrokinra

```bibtex
@misc{secapidev_pdufa_icotrokinra_20261116,
  title        = {ICOTYDE (icotrokinra) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/icotrokinra}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_icotrokinra_20261116","title":"ICOTYDE (icotrokinra) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/icotrokinra","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
